Drugs / 177Lu-NRT6020
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06911489 | Nov 2025 → Oct 2027 expected | cancer | Chengdu New Radiomedicine Technology Co. LTD. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 177Lu-NRT6020 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06911489 ↗ |
| Route | Intravenous | “Participants will receive intravenous injection of 177Lu-NRT6020 Injection, administered Q6W and/or other dosing intervals determined by the SRC, for up to 6 cycles.” NCT06911489 ↗ |